These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 9442546)

  • 41. Combination of clomipramine and nortriptyline in the treatment of obsessive-compulsive disorder: a double-blind, placebo-controlled trial.
    Noorbala AA; Hosseini SH; Mohammadi MR; Akhondzadeh S
    J Clin Pharm Ther; 1998 Apr; 23(2):155-9. PubMed ID: 9786103
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clomipramine and imipramine in obsessive-compulsive disorder.
    Volavka J; Neziroglu F; Yaryura-Tobias JA
    Psychiatry Res; 1985 Jan; 14(1):85-93. PubMed ID: 3887445
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder.
    Heidari M; Zarei M; Hosseini SM; Taghvaei R; Maleki H; Tabrizi M; Fallah J; Akhondzadeh S
    Int Clin Psychopharmacol; 2014 Nov; 29(6):344-50. PubMed ID: 24850229
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacologic treatment of obsessive-compulsive disorder: comparative studies.
    Flament MF; Bisserbe JC
    J Clin Psychiatry; 1997; 58 Suppl 12():18-22. PubMed ID: 9393392
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder.
    Diniz JB; Shavitt RG; Fossaluza V; Koran L; Pereira CA; Miguel EC
    J Clin Psychopharmacol; 2011 Dec; 31(6):763-8. PubMed ID: 22020357
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study.
    Emamzadehfard S; Kamaloo A; Paydary K; Ahmadipour A; Zeinoddini A; Ghaleiha A; Mohammadinejad P; Zeinoddini A; Akhondzadeh S
    Psychiatry Clin Neurosci; 2016 Aug; 70(8):332-41. PubMed ID: 27106362
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.
    Esalatmanesh S; Abrishami Z; Zeinoddini A; Rahiminejad F; Sadeghi M; Najarzadegan MR; Shalbafan MR; Akhondzadeh S
    Psychiatry Clin Neurosci; 2016 Nov; 70(11):517-526. PubMed ID: 27488081
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive-compulsive disorder: A double-blind randomized trial with placebo control.
    Naderi S; Faghih H; Aqamolaei A; Mortazavi SH; Mortezaei A; Sahebolzamani E; Rezaei F; Akhondzadeh S
    Psychiatry Clin Neurosci; 2019 Apr; 73(4):169-174. PubMed ID: 30488617
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genetic and pharmacogenetic study of glutamate transporter (SLC1A1) in Iranian patients with obsessive-compulsive disorder.
    Abdolhosseinzadeh S; Sina M; Ahmadiani A; Asadi S; Shams J
    J Clin Pharm Ther; 2019 Feb; 44(1):39-48. PubMed ID: 30315580
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder.
    Pigott TA; L'Heureux F; Rubenstein CS; Bernstein SE; Hill JL; Murphy DL
    J Clin Psychopharmacol; 1992 Jun; 12(3):156-62. PubMed ID: 1629380
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized controlled trial of Japanese patients with obsessive-compulsive disorder--effectiveness of behavior therapy and fluvoxamine.
    Nakatani E; Nakagawa A; Nakao T; Yoshizato C; Nabeyama M; Kudo A; Isomura K; Kato N; Yoshioka K; Kawamoto M
    Psychother Psychosom; 2005; 74(5):269-76. PubMed ID: 16088264
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.
    Dell'Osso B; Nestadt G; Allen A; Hollander E
    J Clin Psychiatry; 2006 Apr; 67(4):600-10. PubMed ID: 16669725
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder.
    Varigonda AL; Jakubovski E; Bloch MH
    J Am Acad Child Adolesc Psychiatry; 2016 Oct; 55(10):851-859.e2. PubMed ID: 27663940
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators.
    Zohar J; Judge R
    Br J Psychiatry; 1996 Oct; 169(4):468-74. PubMed ID: 8894198
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
    Hollander E; Koran LM; Goodman WK; Greist JH; Ninan PT; Yang H; Li D; Barbato LM
    J Clin Psychiatry; 2003 Jun; 64(6):640-7. PubMed ID: 12823077
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results.
    Pigott TA; Pato MT; Bernstein SE; Grover GN; Hill JL; Tolliver TJ; Murphy DL
    Arch Gen Psychiatry; 1990 Oct; 47(10):926-32. PubMed ID: 2222131
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.
    McDougle CJ; Goodman WK; Leckman JF; Lee NC; Heninger GR; Price LH
    Arch Gen Psychiatry; 1994 Apr; 51(4):302-8. PubMed ID: 8161290
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.
    Goodman WK; Kozak MJ; Liebowitz M; White KL
    Int Clin Psychopharmacol; 1996 Mar; 11(1):21-9. PubMed ID: 8732310
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term efficacy of exposure and ritual prevention therapy and serotonergic medications for obsessive-compulsive disorder.
    Hembree EA; Riggs DS; Kozak MJ; Franklin ME; Foa EB
    CNS Spectr; 2003 May; 8(5):363-71, 381. PubMed ID: 12766692
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacotherapy of primary obsessive-compulsive disorder: review of the literature.
    Ellingrod VL
    Pharmacotherapy; 1998; 18(5):936-60. PubMed ID: 9758307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.